Abstract The coronavirus disease 2019 (COVID-19) pandemic has stimulated tremendous
efforts to develop therapeutic strategies that target severe acute respiratory syndrome …

Vaccines and monoclonal antibody treatments to prevent severe coronavirus disease 2019
(COVID-19) illness were available within a year of the pandemic being declared but there …

The outbreak of COVID-19 has become a global crisis, and brought severe disruptions to
societies and economies. Until now, effective therapeutics against COVID-19 are in high …

There is a large global unmet need for the development of countermeasures to combat
hundreds of viruses known to cause human disease and for the establishment of a …

Background Well tolerated antivirals administered early in the course of COVID-19 infection
when the viremia is highest could prevent progression to severe disease. Favipiravir inhibits …

The COVID-19 pandemic has exemplified that rigorous evaluation in large animal models is
key for translation from promising in vitro results to successful clinical implementation …

Nirmatrelvir is a potent and selective inhibitor of the severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) main protease that is used as an oral antiviral coronavirus …

Introduction Drug repositioning is a strategy to identify a new therapeutic indication for
molecules that have been approved for other conditions, aiming to speed up the traditional …

This COVID‐19 outpatient randomized controlled trials (RCTs) systematic review compares
hospitalization outcomes amongst four treatment classes over pandemic period, geography …

Favipiravir is a broad-spectrum oral antiviral agent that shows in vitro activity against SARS-
CoV-2. Presently, data on the real-world effectiveness and optimal dosage of favipiravir for …